A dangerous hospital fungus may have a new point of vulnerability
Researchers at the University of Wisconsin–Madison say they have identified a promising therapeutic target in Candida auris, a fast-spreading fungal pathogen that has become a major concern in hospitals and long-term care settings worldwide. Their work, reported in Proceedings of the National Academy of Sciences, centers on a gene called TRK1, which appears to be essential for the organism’s growth and its ability to colonize human skin.
The finding matters because Candida auris is unusually difficult to control once it enters healthcare environments. It can persist on skin, spread between patients, contaminate facilities, and resist multiple classes of antifungal drugs. That combination has made it one of the most closely watched emerging fungal threats in modern medicine.
Why Candida auris is such a hard problem
Unlike many fungal pathogens that primarily threaten people with highly specific risk factors, Candida auris has become known for spreading in hospitals and care facilities, where patients may already be vulnerable because of surgery, catheters, or other medical devices. Skin colonization is not necessarily life-threatening on its own, but it creates a dangerous reservoir. If the fungus gains access to the bloodstream or internal tissues, the consequences can be severe.
According to the source article, mortality among patients who develop Candida auris infection is high, often because bloodstream infection can lead to sepsis. Treatment options are limited. There are only three major classes of antifungal drugs, and some strains have already shown resistance to all three. Even the intravenous treatment that still works for many infections has reportedly shown signs of losing effectiveness in some cases.
That clinical backdrop helps explain why researchers are focusing not just on treating invasive infection after it begins, but also on disrupting the fungus earlier in the process. If colonization on skin can be prevented or reduced, downstream infections may become less likely.
The significance of TRK1
The Wisconsin team studied what Candida auris requires to survive under laboratory conditions and on human skin. Their work identified potassium as essential to fungal growth. From there, the researchers created mutant strains with specific genes deleted in order to see which functions the organism could not do without.
One result stood out: removing the TRK1 gene was enough to stop the fungus from growing. The gene controls a protein involved in protection from cationic stress, and the study also found that it is required for colonization of human skin. In practical terms, that makes TRK1 notable for two reasons at once. It appears to support a core survival function, and it also appears necessary for the stage of infection control that hospitals struggle with most: preventing persistent carriage on skin.
That dual role makes the target especially attractive. A therapy aimed at TRK1 could, in principle, do more than slow a pathogen in a petri dish. It could interfere with the fungus’s ability to establish itself on the body surface where it can later spread to patients, devices, and clinical environments.
Why skin colonization is a strategic target
For many healthcare-associated pathogens, colonization is the quiet precursor to severe disease. Candida auris fits that pattern. A patient may carry the organism on skin without immediate symptoms, but the risk rises when medical procedures create a route into the body. In intensive care units and other high-acuity settings, those routes are common.
That is why a colonization-focused strategy could change the way the pathogen is managed. Hospitals currently rely on infection control measures such as screening, isolation practices, and environmental cleaning. Those remain essential, but they do not solve the underlying problem of a fungus that can endure on patients and surfaces while evading standard treatment options.
A drug or topical intervention that blocks the biological mechanisms behind colonization would add a very different tool. Instead of waiting for invasive disease to appear, clinicians could potentially reduce the fungal burden earlier, narrowing opportunities for transmission and severe infection.
What this does and does not mean yet
The new study identifies a promising target, not a finished treatment. That distinction is important. Early-stage target discovery is one of the hardest bottlenecks in antimicrobial development, and clearing that hurdle is scientifically meaningful. But turning a validated target into a safe, effective drug still requires extensive follow-up work, including compound discovery, optimization, toxicity testing, and clinical evaluation.
Even so, the result stands out because fungal drug development has historically lagged behind antibacterial and antiviral research. Fungi are biologically more similar to human cells than bacteria are, which makes selective targeting more difficult. New therapeutic footholds are therefore especially valuable.
The TRK1 finding also reinforces a broader shift in infectious disease research: instead of focusing only on killing pathogens outright, scientists are increasingly interested in disabling the traits that let them persist, spread, and exploit vulnerable patients. In the case of Candida auris, that means understanding how it survives on skin and withstands environmental stresses in clinical settings.
A warning and an opportunity
The emergence of Candida auris has forced health systems to confront a threat that is both microscopic and operational. It is not only a matter of microbiology, but also of hospital workflow, patient safety, and the shrinking margin of error when resistance spreads faster than treatment options.
That is why the identification of TRK1 matters beyond the lab. It offers a plausible starting point for therapies designed around one of the pathogen’s most consequential abilities: colonizing skin, persisting in care environments, and setting the stage for deadly infection. If later work can translate that target into an intervention, it could help shift the fight against Candida auris from containment toward prevention.
For now, the study adds an important piece to a growing body of evidence that the fungus’s biology contains exploitable weak points after all. In a field where resistance has often seemed to outrun drug development, that alone is significant.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
